1-乙基-N,N-二甲基-1H-苯并咪唑-5-胺 | 34594-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-乙基-N,N-二甲基-1H-苯并咪唑-5-胺
• 英文名称: 5-Dimethylamino-1-ethylbenzimidazol
• 英文别名: (1-ethyl-1H-benzoimidazol-5-yl)-dimethyl-amine；1-ethyl-N,N-dimethylbenzimidazol-5-amine
• CAS: 34594-72-4
• 化学式: C₁₁H₁₅N₃
• 分子量: 189.26
• InChiKey: BGNMKQULBLZCGZ-UHFFFAOYSA-N

物化性质

• 沸点：
  329.2±34.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  21.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION
  申请人：Japan Science and Technology Agency

  公开号：EP1800682A1

  公开（公告）日：2007-06-27

  The present invention is to provide a medicinal composition for preventing or treating parasitic protozoan infections, having a high selective toxicity against parasitic protozoan infection, and a superior preventive or treating effect. A medicinal composition for preventing or treating parasitic protozoan infections comprises a compound shown by the following general formula (1) as an active ingredient (wherein R represents an alkyl group, aryl group or heterocyclic group; A and B each independently represents a 5- or 6-membered ring containing at least one hetero atom, or a condensation ring wherein 1 or more 3- to 8-membered ring is condensed thereto; Y represents S, 0, Se, or -NR1-(R1 represents an alkyl group, aryl group or heterocyclic group); L1, L2, L3, L4 and L5 each independently represents a methine group; Q represents a physiologically acceptable anion; k represents an integer of 0 to 2, necessary to make the electric charge of the whole molecule 0; p and q each represents an integer of 0 to 3, wherein the sum of p and q is 1 or more, and 6 or less.)

  本发明旨在提供一种用于预防或治疗寄生性原虫感染的药物组合物，该组合物对寄生性原虫感染具有较高的选择性毒性，并具有优异的预防或治疗效果。一种用于预防或治疗寄生性原生动物感染的药物组合物由以下通式（1）所示的化合物作为活性成分组成 (其中 R 代表烷基、芳基或杂环基团；A 和 B 各自独立地代表含有至少一个杂原子的 5 或 6 元环，或其上缩合有一个或多个 3 至 8 元环的缩合环；Y 代表 S、0、Se 或 -NR1-（R1 代表烷基、芳基或杂环基团）；L1、L2、L3、L4 和 L5 各自独立地代表一个甲基； Q 代表生理上可接受的阴离子； k 代表 0 至 2 的整数，是使整个分子的电荷为 0 所必需的； p 和 q 各自代表 0 至 3 的整数，其中 p 和 q 的和为 1 或以上，6 或以下。)
• ANTI-TRYPANOSOMIASIS AGENT
  申请人：Japan Science and Technology Agency

  公开号：EP1818334A1

  公开（公告）日：2007-08-15

  The present invention is to provide an anti-trypanosomiasis agent having a high selective toxicity, and high preventing or treating effect against trypanosomiasis, comprising a compound shown by the following general formula (1) as an active ingredient (wherein R1 and R2 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C1-5 alkyl group, C1-5 alkoxy group, C5-8 aryl group, C5-8 aryloxy group, C2-6 alkoxycarbonyl group or C2-6 alkylaminocarbonyl group, and may be bound to each other; R3, R4, and R5 each independently represents a C1-5 alkyl group or C5-8 aryl group; R6 and R7 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C1-8 alkyl group, C1-5 alkoxy group, C5-8 aryl group, C5-8 aryloxy group, or C2-6 alkoxycarbonyl group, and may be bound to each other; Y and Z each independently represents an atom group necessary to form a 5- or 6-membered heterocycle; m and n each represent 0 or 1; Q represents a physiologically acceptable anion; k represents an integer of 0 to 2, necessary to make the electric charge of the whole molecule 0) .

  本发明旨在提供一种抗锥虫病制剂，它具有高选择性毒性和高预防或治疗锥虫病的效果，其活性成分包括如下通式(1)所示的化合物 (其中 R1 和 R2 各自独立地代表氢原子、卤素原子、羟基、氧原子、C1-5 烷基、C1-5 烷氧基、C5-8 芳基、C5-8 芳氧基、C2-6 烷氧基羰基或 C2-6 烷氨基羰基，并可相互结合；R3、R4 和 R5 各自独立地代表 C1-5 烷基或 C5-8 芳基；R6 和 R7 各自独立地代表氢原子、卤素原子、羟基、氧原子、C1-8 烷基、C1-5 烷氧基、C5-8 芳基、C5-8 芳氧基或 C2-6 烷氧基羰基，并可相互结合；Y 和 Z 各自独立地代表形成 5 或 6 元杂环所必需的原子团； m 和 n 各自代表 0 或 1； Q 代表生理上可接受的阴离子； k 代表 0 至 2 的整数，是使整个分子的电荷为 0 所必需的。
• PHARMACEUTICAL COMPOSITION COMPRISING AZARHODACYANINE COMPOUND AS ACTIVE INGREDIENT
  申请人：Japan Science and Technology Agency

  公开号：EP1894920A1

  公开（公告）日：2008-03-05

  The object of the invention is to provide pharmaceutical composition that can be used as a therapeutic and/or prophylactic agent. Particularly, the pharmaceutical composition of the invention has significant therapeutic effect and survival benefit for the disease caused by parasitic protozoa, and selective toxicity against the causative protozoa. The pharmaceutical composition comprises a compound represented by general formula (1). Particularly, the invention relates to a composition that is an effective therapeutic/prophylactic agent for malaria, leishmania, African sleeping sickness, Chagas disease, toxoplasmosis lymphatic filariasis, babesiosis, and coccidiosis, and a novel compound contained therein.

  本发明的目的是提供可用作治疗和/或预防剂的药物组合物。特别是，本发明的药物组合物对寄生原虫引起的疾病有显著的治疗效果和生存益处，并对致病原虫有选择性毒性。该药物组合物包含通式（1）所代表的化合物。特别是，本发明涉及一种对疟疾、利什曼病、非洲昏睡病、南美锥虫病、弓形虫病淋巴丝虫病、巴贝丝虫病和球虫病具有有效治疗/预防作用的组合物，以及其中所含的一种新型化合物。
• Anti-Trypanosomiasis Agent
  申请人：Ihara Masataka

  公开号：US20080045574A1

  公开（公告）日：2008-02-21

  The present invention is to provide an anti-trypanosomiasis agent having a high selective toxicity, and high preventing or treating effect against trypanosomiasis, comprising a compound shown by the following general formula (1) as an active ingredient (wherein R 1 and R 2 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C 1-5 alkyl group, C 1-5 alkoxy group, C 5-8 aryl group, C 5-8 aryloxy group, C 2-6 alkoxycarbonyl group or C 2-6 alkylaminocarbonyl group, and may be bound to each other; R 3 , R 4 , and R 5 each independently represents a C 1-5 alkyl group or C 5-8 aryl group; R 6 and R 7 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C 1-8 alkyl group, C 1-5 alkoxy group, C 5-8 aryl group, C 5-8 aryloxy group, or C 2-6 alkoxycarbonyl group, and may be bound to each other; Y and Z each independently represents an atom group necessary to form a 5- or 6-membered heterocycle; m and n each represent 0 or 1; Q represents a physiologically acceptable anion; k represents an integer of 0 to 2, necessary to make the electric charge of the whole molecule 0).
• US7795285B2
  申请人：——

  公开号：US7795285B2

  公开（公告）日：2010-09-14